Industry Perspectives

Refeyn launches software platform to automate mass photometry analysis workflows

New StreamlineMP software suite offers specialized data analysis modules to standardize and speed up workflows in key bioanalytical applications
Written byRefeyn
| 3 min read
Abstract scientific concepts with A scientist pipetting in the background

Credit: iStock.com/ metamorworks

Register for free to listen to this article
Listen with Speechify
0:00
3:00

Original story from Refeyn.

A screenshot showing the interface of mass photometry data analysis software

Refeyn’s new StreamlineMP modular software platform offers automated data analysis for specific mass photometry applications.

Oxford, UK (26 November, 2024)Refeyn, the company behind pioneering mass photometry technologies, has developed and launched a custom software platform providing automated analysis of large mass photometry data sets. Refeyn’s new StreamlineMP software suite offers specialist analysis modules, automating data processing through standardized workflows for key bioanalytical applications to deliver more consistent results in a shorter time.

StreamlineMP is a complementary modular software platform to DiscoverMP, Refeyn’s well-established and powerful data analysis software which accommodates a wide range of analytical options. DiscoverMP offers broad flexibility that is highly desirable for many users, yet for some, who want a standardized analysis workflow across a large number of datasets, it can prove time consuming. Through its suite of application-specific module options, StreamlineMP supports these customers who need to apply repeated analysis parameters to large datasets for individual applications. Its use reduces analysis time and ensures the consistency of analytical parameters, which are not automatically standardized across users when analysis is carried out manually.

The first application-specific module to be added to the new StreamlineMP software suite is Refeyn’s Antibody Stability Module, which automatically characterizes aggregation in large batches of antibody samples in a fraction of the time required for manual analysis. This dedicated software module delivers robust statistics on aggregation levels for replicate groups. Designed for extensive datasets obtained in antibody stability analysis, the module enables a simple comparison of stress conditions or antibody types. This is an ideal solution for monitoring aggregation as a critical quality attribute (CQA) for therapeutic antibodies.

Cutting the analysis time of antibody data by 80% or more, this new StreamlineMP module’s automated data analysis complements the high speed, resolution and sensitivity of mass photometry, providing unrivalled insights into antibody aggregation. The Antibody Stability Module offers: A guided workflow, the ability to group replicate measurements for statistical analysis, and output of the key parameters characterizing the aggregation of the antibodies in the sample.

“Recognizing our customer needs and further enhancing the speed and ease-of-use of our expanding mass photometry range, we’re pleased to introduce StreamlineMP to offer tailored solutions for the automation of large dataset analysis,” said Fiona Coats, Chief Marketing Officer at Refeyn. “Combined with the strengths of mass photometry as a rapid, reliable solution for antibody aggregation analysis, we see our first software application, the Antibody Stability Module, becoming an essential tool for in-process purity and stability analysis for therapeutic antibodies.”

Proving the efficacy of its new StreamlineMP automated aggregation analysis capabilities, Refeyn has also released a tech note discussing “Quantifying antibody aggregation at nano- and micromolar sample concentrations with the mass photometry Antibody Stability Module”. Here, Refeyn’s TwoMP mass photometer and MassFluidix® HC rapid dilution add-on are used with the Antibody Stability Module to efficiently analyze aggregation in a selection of antibody standards. The new antibody aggregation tech note shows the speed and ease by which antibody aggregation can be quantified using mass photometry analysis streamlined with the new Antibody Stability Module.

To find out more about Refeyn and its novel mass photometry technologies, please visit: https://www.refeyn.com

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release republishing policy can be accessed here.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
3D illustration of a membrane protein embedded within a lipid nanodisc, representing a native-like environment used for membrane protein stabilization and characterization.
Mass photometry supports membrane protein characterization by providing rapid insights into sample composition, purity, and molecular assembly.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue